MBIO

Mustang BioD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$0.90

+18.2% vs current

Most likely

Base case

45%

Probability

Target price

$0.50

-34.3% vs current

B-

Bear case

30%

Probability

Target price

$0.25

-67.2% vs current

AI sentiment snapshot

Latest data as of 2026-05-15

AI commentary

Primary-source evidence is solid because the April 17, 2026 8-K and May 5, 2026 10-Q are available, but post-earnings interpretation is still thin. The market reaction was weak after the Q1 filing: MBIO closed at $0.77 on May 5, 2026, then drifted to $0.66 by May 12, 2026 and $0.63 by May 14, 2026, suggesting the market focused more on listing/dilution constraints than on the lower burn profile. The added long-horizon financing catalyst remains cautious because it depends on runway execution and capital access rather than a confirmed partnership, pivotal trial, or approved product. Fresh analyst revision and target-change coverage was not available in checked sources, so this remains a low-coverage monitoring memo rather than a high-conviction call.

RankAlpha Sentiment Codex - 2026-05-15

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31catalystPost-Q1 2026 filing digestion centers on runway rather than revenue upsideHigh impact

The Q1 2026 10-Q showed cash and cash equivalents of $16.3 million at March 31, 2026, a Q1 net loss of about $1.0 million, and management stating cash is sufficient for at least twelve months from issuance of the financial statements; this is the key post-earnings support point because no separate Q1 2026 earnings release is listed on the company IR financial-results page as of May 15, 2026. [#10-Q-2026-05-05]

2026-09-30eventMB-109 investigator-sponsored study timing is the main clinical forward hookHigh impact

Mustang said it is exploring with City of Hope and Nationwide the possibility of initiating an investigator-sponsored single-institution MB-109 study in the third quarter of 2026 after prior MB-101 and MB-108 Phase 1 treatment phases completed; confirmation of study initiation would be the clearest program-specific upside catalyst from here. [#10-Q-2026-05-05]

2026-10-12catalystCapital structure and listing remediation remain dominant overhangsHigh impact

The company is below Nasdaq's $1.00 minimum bid requirement, with a cure deadline of October 12, 2026, and its 10-Q says it is subject to Form S-3 baby-shelf limits, constraining primary capital raising flexibility; if MBIO cannot regain compliance organically, reverse-split and dilution risk remain central to the thesis. [#8-K-2026-04-17] [#10-Q-2026-05-05]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-15 • Updated nightlySource: Internal modelMethodology